Novavax stock falls 2.59 percent below its yearly high

Published on 09/24/2026 at 12:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novavax stock stood at USD 10.55 on September 23, 2026, within a USD 6.20 to USD 11.97 52-week range. Q2 revenue reached USD 56.7 million.

Novavax stock, biotechnology, quarterly earnings, Nasdaq, Illustration mit AI erstellt.

Novavax stock (ISIN US6700024010) fell 2.59 percent to USD 10.55 on Nasdaq on September 23, 2026. The move leaves the biotechnology company 11.87 percent below its 52-week high of USD 11.97, while its market capitalization stood at USD 1.734 billion.

Quarterly revenue sets the baseline

Novavax reported USD 56.7 million in revenue for the second quarter of 2026, compared with a consensus estimate of USD 53.3 million. Adjusted EPS came in at negative USD 0.32, beating the consensus estimate of negative USD 0.38.

The figures show a mixed operating picture: revenue exceeded expectations by USD 3.4 million, but the company still reported a loss on an adjusted per-share basis. According to MarketBeat, the second-quarter EPS result was USD 0.06 better than the consensus estimate.

The yearly range shows the tension

At USD 10.55, the shares remained USD 1.42 below the 52-week high and USD 4.35 above the 52-week low of USD 6.20. That spread places the stock closer to the top of its yearly range than to the bottom, even after the September 23 decline.

The comparison matters because the market value remains sensitive to changes in vaccine expectations and quarterly revenue timing. Novavax ended the session with a daily trading range of USD 10.46 to USD 10.95, giving investors a clear measure of the day's volatility.

Novavax stock stays above USD 10

Novavax stock stood at USD 10.55 on Nasdaq on September 23, 2026, after the prior session closed at USD 10.83. The next market signal will come from whether the stock holds above the USD 10 level while revenue performance remains ahead of quarterly consensus.